The supplied record set for Koh Young Technology, Inc. contains a single linked 510(k) entry, Geniant Cranial, with a substantially equivalent decision dated September 10, 2026. The applicant address in the FDA record is in Yeoju, Republic of Korea, and the same address appears in the FDA clearance letter. Company-published pages describe Geniant Cranial as a navigated neurosurgical robot platform and state that it is cleared and available in the United States, approved and available in South Korea, and approved and available in Japan. [1][2][3]

The documented product and its regulatory identity

Geniant Cranial is filed as a Navigated Neurosurgical Positioning Robot under 21 CFR 882.4560, Stereotaxic Instrument, Class II, product code HAW, with the advisory committee listed as Neurology. The FDA record gives a decision of SESE, described as Substantially Equivalent, with a Traditional clearance type and a summary statement. The device name in the openFDA classification data is Neurological Stereotaxic Instrument. [1][2]

The applicant is Koh Young Technology, Inc., with a contact listed as Sooji Shin, RA Team Leader. The address in the FDA record is 1f, 66-27, Gwangdae 2-Gil, Sejongdaewang-Myeon, Yeoju-Si, in the Republic of Korea. That address is a filing address and does not establish a corporate headquarters. [1][2]

Submission dates and review sequence

For K253856, the FDA record lists a date received of December 3, 2025, and a decision date of September 10, 2026. The clearance letter carries the same decision date and describes the submission as dated and received June 12, 2026. The two dates are reported as they appear in the respective sources. [1][2]

A separate FDA clearance letter in the sources addresses K241333, also titled Geniant Cranial (Navigated Neurosurgical Positioning Robot), under the same regulation number, class and product code, dated January 17, 2025, with the submission dated and received December 18, 2024. That letter is not part of the linked portfolio record sample, which contains only K253856. [6]

Company-published descriptions and design claims

Koh Young's product page describes Geniant Cranial as a next-generation navigated robotic guidance platform with optical tracking accuracy, software and patient positioning features, and states clearance and availability in the United States, approval and availability in South Korea, and approval and availability in Japan. These are company statements attributed to the publisher. [3]

The Geniant Cranial site describes the system as a next-generation navigated neurosurgical robot designed for stereotactic neurosurgeries, citing a Red Dot Award for product design and listing accuracy, safety and innovation themes that include a 2-in-1 robot and navigation system and collision prevention. The Geniant about page frames Geniant as a medical platform that began with neurosurgery. These descriptions originate with the company. [5][7]

What the supplied record does and does not show

The linked portfolio contains one record, in the 510(k) pathway, with one SESE decision; the record sample likewise contains one entry, K253856. These counts describe the supplied filings as of the snapshot and are not measures of total company sales, total portfolio or safety performance. No recall records appear in the supplied sample. [1]

The K253856 clearance letter includes a table with registration-related values labeled Bone Fiducial Registration and Tracing Registration, alongside confidence interval notation. The public information does not establish what those values measure, so their meaning remains unknown here. The company's 2025 sustainability report lists Geniant Cranial receiving a U.S. clearance among 2025 items. [2][8]